Beta-Adrenergic Receptor Blocking Drugs
- 17 November 1966
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 275 (20) , 1106-1112
- https://doi.org/10.1056/nejm196611172752006
Abstract
THE concept that effector cells contain excitatory and inhibitory "receptor substances" and that the effects of epinephrine are dependent upon the types of receptor substances present was first suggested by Langley1 more than sixty years ago. This hypothesis received support in 1906, when Dale's2 comprehensive studies on the adrenergic blocking activity of ergot derivatives was published. Although these drugs completely antagonized and even reversed the excitatory actions of epinephrine they had no effect on the inhibitory actions. The only excitatory action of epinephrine that was not inhibited by ordinary doses of ergot was its stimulation of the heart. These results . . .Keywords
This publication has 34 references indexed in Scilit:
- The prophylactic value of propranolol in angina pectorisThe American Journal of Cardiology, 1966
- Multicenter trial of propranolol in angina pectorisThe American Journal of Cardiology, 1966
- Effects of beta adrenergic blockade on heart sizeThe American Journal of Cardiology, 1966
- Propranolol in the therapy of angina pectorisThe American Journal of Cardiology, 1966
- Effects of propranolol on peripheral vessels in manThe American Journal of Cardiology, 1966
- Hemodynamic changes after beta adrenergic blockadeThe American Journal of Cardiology, 1966
- The Effect of a β-Adrenergic-Blocking Agent (Nethalide) and Nitroglycerin on Exercise Tolerance in Angina PectorisCirculation, 1965
- Carcinogenic Action of PronethalolBMJ, 1963
- PHARMACOLOGY OF A NEW ADRENERGIC BETA-RECEPTOR-BLOCKING COMPOUND (NETHALIDE)The Lancet, 1962
- STUDIES IN DIURNAL VARIATION OF WATER AND ELECTROLYTE EXCRETION: NOCTURNAL DIURESIS OF WATER AND SODIUM IN CONGESTIVE CARDIAC FAILURE AND CIRRHOSIS OF THE LIVER 12Journal of Clinical Investigation, 1951